ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Merus NV

Merus NV (2GH)

42.20
0.80
(1.93%)
Closed December 08 4:00PM
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
42.20
Bid
41.80
Ask
42.80
Volume
0.00
0.00 Day's Range 0.00
21.40 52 Week Range 58.50
Previous Close
41.40
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
127
Financial Volume
-
VWAP
-

2GH Latest News

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt

Merus und Partner Therapeutics geben Lizenzvereinbarung für die Vermarktung von Zenocutuzumab in den USA bei NRG1-fusionspositivem Krebs bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts...

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive

Merus et Partner Therapeutics annoncent un contrat de licence en vue de la commercialisation aux États-Unis du zenocutuzumab dans le cadre du traitement des cancers à fusion NRG1 positive UTRECHT...

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02...

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 – Petosemtamab 1500 mg monotherapy phase 2 interim data continues to...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1-2.3148148148143.2474319244.19451697DE
4-7.8-15.65051.540.411744.74603537DE
12-3-6.6371681415945.251.540.412747.17167127DE
26-6-12.448132780148.257.540.415948.57608533DE
5219.283.47826086962358.521.39999917344.34418355DE
15618.477.310924369723.858.51916742.00023485DE
26018.477.310924369723.858.51916742.00023485DE

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M
A6NAsana Inc
21.00 €
(43.84%)
19.08k
NL8Genesis Ai Corp
0.0214 €
(40.79%)
13.33k
RQ0DWave Quantum Inc
4.814 €
(34.92%)
1.15M
K8DWellfield Technologies Inc
0.0342 €
(34.65%)
30.8k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
M0YNMynaric AG
1.40 €
(-72.66%)
303.13k
W47Grid Battery Metals Inc
0.0115 €
(-39.47%)
7
47GAGo Metals Corp
0.0202 €
(-36.88%)
3.44k
4APApollo Minerals Ltd
0.0055 €
(-35.29%)
270.7k
AXIAtos SE
0.0028 €
(-98.58%)
1.59B
D7GNel ASA
0.2625 €
(-1.69%)
4.24M
LK1Lake Resources
0.029 €
(-6.75%)
2.32M
TUI1Tui AG
8.40 €
(1.11%)
2.17M
TE9Teco 2030 ASA
0.0592 €
(65.36%)
2.11M

Discussion

View Full Feed
littlejohn littlejohn 3 minutes ago
12/06/2024, SMCI granted Nasdaq extension to

allow time to complete late filings...

Extended until 02/25/2025...

https://www.otcmarkets.com/filing/html?id=18031289&guid=3ZY-knwqaje5h3h


SuperMicro can help make AI Cool...
SMCI
4u2nv2 4u2nv2 4 minutes ago
Hello Chucky. Can MCIC do this? (you seem well informed) "With a reverse triangular merger, it is usually easier to obtain consent from company shareholders because the new subsidiary company has only one shareholder: the public share company. Structuring a reverse merger in this way allows the publ
MCIC
StayHumble StayHumble 4 minutes ago
✅wow!Lots of interest here in $GNCP wow!✅✅✅✅
GNCP
Carjockey2 Carjockey2 4 minutes ago
Technicalities are impossible to figure out and or any stock price that's why I stay away from guessing or posting them.....simply because I don't want to ass/u/me them.
NorthPeak22 NorthPeak22 4 minutes ago
From NIA:

When we show you this photo of the One Stop Systems (OSS) Gen5 4UPro Accelerator System, this is a product meant for AI data centers like the ones being built by CoreWeave:
https://investorshub.advfn.com/uimage/uploads/2024/12/8/koftniMarkup_20241208_222239.jpg
NVDA OSS SMCI
georgejjl georgejjl 4 minutes ago
Expect a press release TOMORROW concerning AVXL!!!

Good luck and GOD bless,
AVXL
Streett Streett 4 minutes ago
I thought and think so, too... O am so glad they are holding the spaces again.... really good people there...
HMBL
dalesio_98 dalesio_98 5 minutes ago
OMG SMH ... next excuse ...

Good luck to All!
StayHumble StayHumble 6 minutes ago
wow✅.000001 BUYS💹MASSIVE SHORT Position Here💹https://ih.advfn.com/stock-market/USOTC/omni-health-ce-OMHE/trades
OMHE
Streett Streett 7 minutes ago
To say that with such conviction based on a heart attached to a post is a bit of a reach.  He could have given the heart for the "Welcome aboard" part only....
HMBL
excel excel 7 minutes ago
The Chiefs. LOL!

At least no help from the refs.
StayHumble StayHumble 7 minutes ago
wow $5.3 BILLION✅✅Xplains the interest here✅ ✅ ✅ ✅
NRDE
KingRichard3rd KingRichard3rd 8 minutes ago
To all longs.

Definitely pay attention to both AMC & GME on Tuesday after market close.
GME will post earnings on Tuesday, and our famous Roaring Kitty can bring both stocks up at 1:09 (PT)!!!
Good luck!
AMC GME
devil dog 96 devil dog 96 9 minutes ago
Why is it so hard for you to show us a ticker with the same micro unrestricted share count as ATMH with a share price under 10 cents like ATMH's? Is it because you can't find one or do you not want to prove me wrong? 😃 LMAO

" More repeat non sense from the condog 🤡mani
ATMH
MiamiGent MiamiGent 9 minutes ago
President-elect Trump needs to find a place for Sydney Powell!
biowin biowin 12 minutes ago
What a coincidence this happens with Tlgy acquisition corp, and continental trust when Bioamber Sarnia, Canada is dissolved??? They could take Lcyb public into a merger with the buyout of Bioamber shares

https://www.sec.gov/ix?doc=/Archives/edgar/data/1879814/000110465924125922/tm2
rosemountbomber rosemountbomber 15 minutes ago
There is no question that it seems that the Healthnet settlement accomplished very little.  Heck maybe it was Amarin that wanted the settlement details sealed. 
AMRN
GrandAdmiralThrawn GrandAdmiralThrawn 15 minutes ago
What do you think the timeline is on this getting done, they are just like us, so we can't really take their information as anything other than opinion. What's your opinion, I trust your opinion over theirs anyways
Petroleum2024 Petroleum2024 16 minutes ago
🚀🚀🚀🚀🌙 🌙🌙🌙🌙
HCMC
dalesio_98 dalesio_98 16 minutes ago
I obtained the Dissolution documents.

Good luck to All!

https://investorshub.advfn.com/uimage/uploads/2024/12/8/vhjroScreenshot_20241208_224649_Chrome.jpg
GrandAdmiralThrawn GrandAdmiralThrawn 17 minutes ago
Well they are thinking sometime next year this should all be finalized. I mean lets talk on your board
HMBL

Your Recent History

Delayed Upgrade Clock